ReviewInterventional cardiology (London, England)2025
Transcatheter Aortic Valve Replacement for Aortic Insufficiency.
Review in Interventional cardiology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Aortic Valve Migration and Embolization During Transcatheter Aortic Valve Replacement: A Contemporary Management Review With a Practical Bailout Algorithm.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter aortic valve replacement (TAVR) has developed into a viable treatment for aortic regurgitation (AR), particularly in high-risk or elderly patients unable to undergo surgery. Early generation devices encountered significant challenges, including high mortality rates, residual paravalvular leaks, and complications such as valve embolisation. However, advancements in TAVR technology, including self-expanding and balloon-expandable devices, have improved procedural outcomes. Dedicated devices, such as the Trilogy system (JenaValve) and J-Valve (Edwards Lifesciences), specifically designed for AR, have demonstrated superior performance with reduced complications and better patient survival. Other devices, such as Cusper (Cuspa) and the Zeta/Alpha systems (Laguna Tech), show potential for treating complex AR cases, including those with non-calcified valves or active endocarditis. These innovations offer hope for patients with severe AR, highlighting the need for tailored approaches based on individual anatomical and pathological variations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.